Cita APA (7a ed.)
Xu, H., Wang, L., Lou, Y., Qiu, Z., & Xuan, F. (2026). Benmelstobart Plus Anlotinib Is Unlikely to Be Cost-Effective for Advanced Renal Cell Carcinoma: An Integrated Disease Burden and Cost-Effectiveness Analysis. Inquiry (00469580), 63, 1-18.
Cita Chicago Style (17a ed.)
Xu, Haiyan, Liejiong Wang, Ying Lou, Zhaoqi Qiu, y Feng Xuan. "Benmelstobart Plus Anlotinib Is Unlikely to Be Cost-Effective for Advanced Renal Cell Carcinoma: An Integrated Disease Burden and Cost-Effectiveness Analysis." Inquiry (00469580) 63 (2026): 1-18.
Cita MLA (9a ed.)
Xu, Haiyan, et al. "Benmelstobart Plus Anlotinib Is Unlikely to Be Cost-Effective for Advanced Renal Cell Carcinoma: An Integrated Disease Burden and Cost-Effectiveness Analysis." Inquiry (00469580), vol. 63, 2026, pp. 1-18.
Precaución: Estas citas no son 100% exactas.